LAB INDEX

Showing search results for "Age Group"

  • Impact
  • Papers
  • Jobs
  • Conferences
Name Impact
?

Papers Institution Country Funding

Chayama, Kazuaki

248.6 40 Hiroshima University Japan -

Jemal, Ahmedin

211.6 2 Epidemiologist, Surveillance and Health Services Research, American Cancer Society, Atlanta, GA. USA -

Kumada, Hiromitsu

198.8 48 Toranomon Hospital Japan -

Chung, Raymond T

196.8 26 University of Texas Southwestern Medical Center USA $29,286,306.00

Rehermann, Barbara

192.9 16 National Institutes of Health USA $10,585,476.00

187.6 16 N/A -

Narod, S A

185.5 19 Mount Sinai Hospital Canada -

Fan, Jia

181.6 27 Fudan University China -

Baumert, Thomas F

171.7 19 Inserm, U748, Strasbourg France -

Zeuzem, Stefan

164.6 25 J.W. Goethe-University Hospital Germany -

Rice, Charles M

162.5 14 The Rockefeller University USA $21,689,683.00

Berry, Donald A

159.9 1 University of Vermont USA $15,196,711.00

Lemon, Stanley M

157.9 21 The University of North Carolina at Chapel Hill USA $25,311,624.00

Bartenschlager, Ralf

153.6 19 Heidelberg University Germany -

El-Serag, Hashem B

151.6 20 Baylor College of Medicine USA $5,962,295.00

Cheng, Ann-Lii

149.9 23 National Taiwan University Hospital Taiwan -

McHutchison, John G

147.3 13 Duke University Medical Center USA -

Cacoub, P

145.8 22 Laboratoire de Biologie et Thérapeutique des Pathologies Immunitaires, Centre National de la Recherche Sientifique, Universite Pierre et Marrie C… France -

Bukh, Jens

145.6 18 Copenhagen University Hospital Denmark -

Pineda, Juan A

144.4 22 Hospital Universitario de Valme Spain -

Couch, Fergus J

141.3 7 University of Southern California/Norris Comprehensive Cancer Center USA -

Pietschmann, Thomas

139.2 18 Centre for Experimental and Clinical Infection Research Germany -

Maehara, Yoshihiko

136.6 35 Aso Iizuka Hospital Japan -

Llovet, Josep M

133 13 Mount Sinai School of Medicine USA $997,264.00

McKeating, Jane A

129.8 18 University of Birmingham UK $216,490.00

Colombo, Massimo

129.8 22 University of Milan Italy -

Cristofanilli, M

124.1 3 Dubai Hospital United Arab Emirates -

Marcellin, P

123.4 20 INSERM, U773, Centre de Recherche Bichat-Beaujon CRB3, Paris France -

Pawlotsky, Jean-Michel

122.9 18 Department of Virology, Hôpital Henri Mondor, Université Paris-Est Créteil France -

Soriano, V

120 23 Hospital Carlos III Spain -

Naghavi, Mohsen

114.8 1 University of Washington USA -

Dore, Gregory J

110.6 20 The University of New South Wales Australia -

McCarthy, Ellen P

110.2 2 Beth Israel Deaconess Medical Center, 1309 Beacon, Office 202, Brookline, MA 02446 USA -

Buchholz, Thomas A

108.6 5 The University of Texas MD Anderson Cancer Center USA -

Perelson, Alan S

107.9 15 Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545 USA $5,462,450.00

Thimme, Robert

107.4 14 University of Freiburg Germany -

Ploss, Alexander

104.6 8 The Rockefeller University USA $625,646.00

He, Xianghuo

104.2 14 Fudan University China -

Covey, Anne

101.7 1 Indiana University School of Medicine USA -

Sestak, Ivana

99.1 2 Queen Mary University of London UK -

Wedemeyer, H

98 20 Hannover Medical School Germany -

Sulkowski, Mark S

94.6 9 Johns Hopkins University School of Medicine USA -

Liang, T Jake

91 8 National Institutes of Health USA $14,690,785.00

Tamimi, Rulla M

90.5 9 Dana-Farber Cancer Institute USA $15,347,877.00

Ray, Ranjit

89.2 14 Saint Louis University USA $3,735,526.00

Wei, Lin

88.1 17 Hebei Medical University China $271,189.00

Nguyen, M H

88 17 Stanford University Medical Center USA -

Prins, M

87.9 13 Department of Experimental Virology, Center for Infection and Immunology Amsterdam (CINIMA), Academic Medical Center, Amsterdam Netherlands -

Kato, Nobuyuki

87.5 20 Okayama University Graduate School of Medicine Japan -

Resino, S

86.3 20 Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid Spain -
Name Institution Date Impact Publication

Jemal, Ahmedin

Epidemiologist, Surveillance and Health Services Research, American Cancer Society, Atlanta, GA. 10/01/2013 101.70 CA: a cancer journal for clinicians
Breast cancer statistics, 2013. Abstract

Covey, Anne

Indiana University School of Medicine 10/15/2012 101.70 CA: a cancer journal for clinicians
Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. Abstract

Cristofanilli, Massimo

The University of Texas M. D. Anderson Cancer Center 10/19/2010 101.70 CA: a cancer journal for clinicians
Inflammatory breast cancer: the disease, the biology, the treatment. Abstract

McHutchison, John G

Duke University Medical Center 06/23/2011 53.29 The New England journal of medicine
Telaprevir for previously untreated chronic hepatitis C virus infection. Abstract

Berry, Donald A

University of Vermont 05/14/2009 53.29 The New England journal of medicine
Adjuvant chemotherapy in older women with early-stage breast cancer. Abstract

Sestak, Ivana

Queen Mary University of London 12/12/2013 38.27 Lancet
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Abstract

Naghavi, Mohsen

University of Washington 09/14/2011 38.27 Lancet
Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Abstract

Ploss, Alexander

The Rockefeller University 07/31/2013 36.28 Nature
Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Abstract

Ploss, Alexander

The Rockefeller University 06/08/2011 36.28 Nature
A genetically humanized mouse model for hepatitis C virus infection. Abstract

Rice, Charles M

The Rockefeller University 01/28/2009 36.28 Nature
Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Abstract

Couch, Fergus J

University of Southern California/Norris Comprehensive Cancer Center 10/30/2011 35.53 Nature genetics
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Abstract

Chayama, Kazuaki

Hiroshima University 07/03/2011 35.53 Nature genetics
Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Abstract

Tamimi, Rulla M

Harvard School of Public Health 01/30/2011 35.53 Nature genetics
Common variants in ZNF365 are associated with both mammographic density and breast cancer risk. Abstract

Couch, Fergus J

Mayo Clinic College of Medicine 09/19/2010 35.53 Nature genetics
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Abstract

Sulkowski, Mark S

Johns Hopkins University School of Medicine 07/23/2012 30.02 JAMA
Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. Abstract

Llovet, Josep M

Mount Sinai School of Medicine 02/17/2010 26.56 Cancer cell
Obesity, inflammatory signaling, and hepatocellular carcinoma-an enlarging link. Abstract

Rice, Charles M

The Rockefeller University 01/31/2010 23.26 Nature biotechnology
Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Abstract

11/17/2010 22.58 The Lancet. Oncology
Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single-arm, FH01 study. Abstract

Sestak, Ivana

Queen Mary University of London 11/17/2010 22.58 The Lancet. Oncology
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Abstract

Cheng, Ann Lii

Beaujon University Hospital 07/06/2009 22.58 The Lancet. Oncology
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Abstract

Rehermann, Barbara

National Institutes of Health 11/24/2013 22.46 Nature medicine
Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection. Abstract

Rice, Charles M

The Rockefeller University 07/09/2013 22.46 Nature medicine
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Abstract

Rehermann, Barbara

National Institutes of Health 07/09/2013 22.46 Nature medicine
Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Abstract

Liang, T Jake

National Institutes of Health 05/26/2013 22.46 Nature medicine
Hepatitis C virus infection activates an innate pathway involving IKK-α in lipogenesis and viral assembly. Abstract

Baumert, Thomas F

Inserm, U748, Strasbourg 04/24/2011 22.46 Nature medicine
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Abstract

Royal Derby Hospital 05/24/2012 21.18 Nature reviews. Microbiology
The drugs can work. Abstract

Lemon, Stanley M

The University of North Carolina at Chapel Hill 04/29/2009 20.00 Annual review of pathology
Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer. Abstract

He, Xianghuo

Fudan University 03/21/2010 19.48 Nature cell biology
Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Abstract

Fan, Jia

Fudan University 11/21/2011 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. Abstract

Buchholz, Thomas A

The University of Texas MD Anderson Cancer Center 11/07/2011 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Improvement in breast cancer outcomes over time: are older women missing out? Abstract

Narod, Steven A

University of Toronto 03/28/2011 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. Abstract

McCarthy, Ellen P

Beth Israel Deaconess Medical Center, 1309 Beacon, Office 202, Brookline, MA 02446 03/14/2011 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Causes of death and relative survival of older women after a breast cancer diagnosis. Abstract

McCarthy, Ellen P

Beth Israel Deaconess Medical Center, 1309 Beacon, Office 202, Brookline, MA 02446 03/22/2010 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. Abstract

Buchholz, Thomas A

the University of Texas MD Anderson Cancer Center 04/29/2009 18.37 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Future of cancer incidence in the United States: burdens upon an aging, changing nation. Abstract

Prins, Maria

University of California 04/30/2012 17.39 The Lancet. Infectious diseases
Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Abstract

Royal Derby Hospital 09/12/2013 16.73 Annals of internal medicine
Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Abstract

El-Serag, Hashem B

Baylor College of Medicine 01/18/2011 16.73 Annals of internal medicine
Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Abstract

Wei, Li

University of Dundee 07/13/2012 16.38 BMJ (Clinical research ed.)
Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study. Abstract

Baumert, Thomas F

Inserm, U748, Strasbourg 08/16/2010 13.85 The Journal of experimental medicine
Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. Abstract

Narod, Steven A

The University of Toronto 11/21/2013 13.75 Journal of the National Cancer Institute
PPM1D mutations in circulating white blood cells and the risk for ovarian cancer. Abstract

Tamimi, Rulla M

Washington University in St Louis School of Medicine 07/27/2011 13.75 Journal of the National Cancer Institute
Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics. Abstract

Baumert, Thomas F

Inserm, U748, Strasbourg 03/18/2013 13.50 Cell host & microbe
HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Abstract

Bartenschlager, Ralf

Heidelberg University 07/23/2012 13.50 Cell host & microbe
Dynamic oscillation of translation and stress granule formation mark the cellular response to virus infection. Abstract

Bartenschlager, Ralf

Heidelberg University 01/17/2011 13.50 Cell host & microbe
Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Abstract

Chung, Raymond T

Harvard Medical School 03/16/2009 13.50 Cell host & microbe
A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Abstract

Chung, Raymond T

Harvard Medical School 09/14/2011 13.10 Annual review of medicine
Novel therapies for hepatitis C: insights from the structure of the virus. Abstract

Ploss, Alexander

The Rockefeller University 02/22/2010 13.06 The Journal of clinical investigation
New horizons for studying human hepatotropic infections. Abstract

Rehermann, Barbara

National Institutes of Health 07/01/2009 13.06 The Journal of clinical investigation
Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. Abstract

Rice, Charles M

The Rockefeller University 02/03/2009 13.06 The Journal of clinical investigation
Predicting response to hepatitis C therapy. Abstract

Thimme, Robert

University of Freiburg 01/12/2009 13.06 The Journal of clinical investigation
Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response. Abstract

Narod, Steven A

Womens College Research Institute 06/26/2012 11.96 Nature reviews. Clinical oncology
Breast cancer in young women. Abstract

Bukh, Jens

Copenhagen University Hospital 11/18/2013 11.67 Gastroenterology
Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors. Abstract

Llovet, Josep M

Mount Sinai School of Medicine 01/09/2013 11.67 Gastroenterology
Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Abstract

Thimme, Robert

University of Freiburg 11/07/2012 11.67 Gastroenterology
Factors that determine the antiviral efficacy of HCV-specific CD8(+) T cells ex vivo. Abstract

Rehermann, Barbara

National Institutes of Health 06/13/2012 11.67 Gastroenterology
Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus. Abstract

El-Serag, Hashem B

Baylor College of Medicine 04/27/2012 11.67 Gastroenterology
Epidemiology of viral hepatitis and hepatocellular carcinoma. Abstract

Bukh, Jens

Copenhagen University Hospital 04/27/2012 11.67 Gastroenterology
Animal models for the study of hepatitis C virus infection and related liver disease. Abstract

Pawlotsky, Jean-Michel

Department of Virology, Hôpital Henri Mondor, Université Paris-Est Créteil 04/27/2012 11.67 Gastroenterology
New virologic tools for management of chronic hepatitis B and C. Abstract

Sulkowski, Mark S

Johns Hopkins University School of Medicine 04/27/2012 11.67 Gastroenterology
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Abstract

Bartenschlager, Ralf

Heidelberg University 04/19/2012 11.67 Gastroenterology
Persistence of HCV in quiescent hepatic cells under conditions of an interferon-induced antiviral response. Abstract

Baumert, Thomas F

Inserm, U748, Strasbourg 04/10/2012 11.67 Gastroenterology
Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. Abstract

Pietschmann, Thomas

Centre for Experimental and Clinical Infection Research 03/27/2012 11.67 Gastroenterology
A plant-derived flavonoid inhibits entry of all HCV genotypes into human hepatocytes. Abstract

Liang, T Jake

National Institutes of Health 01/13/2012 11.67 Gastroenterology
HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Abstract

McKeating, Jane A

University of Birmingham 12/01/2011 11.67 Gastroenterology
Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Abstract

Rehermann, Barbara

National Institutes of Health 07/07/2011 11.67 Gastroenterology
Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Abstract

Bartenschlager, Ralf

Heidelberg University 06/13/2011 11.67 Gastroenterology
Mouse hepatic cells support assembly of infectious hepatitis C virus particles. Abstract

Bukh, Jens

Copenhagen University Hospital 06/12/2011 11.67 Gastroenterology
Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Abstract

Rehermann, Barbara

National Institutes of Health 05/18/2011 11.67 Gastroenterology
Delayed induction, not impaired recruitment, of specific CD8⁺ T cells causes the late onset of acute hepatitis C. Abstract

Pawlotsky, Jean-Michel

Department of Virology, Hôpital Henri Mondor, Université Paris-Est Créteil 03/24/2011 11.67 Gastroenterology
High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial). Abstract

Llovet, Josep M

Mount Sinai School of Medicine 03/13/2011 11.67 Gastroenterology
Targeted therapies for hepatocellular carcinoma. Abstract

Llovet, Josep M

Mount Sinai School of Medicine 02/13/2011 11.67 Gastroenterology
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Abstract

Llovet, Josep M

Mount Sinai School of Medicine 02/12/2011 11.67 Gastroenterology
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Abstract

Fan, Jia

Fudan University 02/12/2011 11.67 Gastroenterology
CD151 amplifies signaling by integrin α6β1 to PI3K and induces the epithelial-mesenchymal transition in HCC cells. Abstract

El-Serag, Hashem B

Baylor College of Medicine 12/22/2010 11.67 Gastroenterology
Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Abstract

Sulkowski, Mark S

Johns Hopkins University School of Medicine 12/04/2010 11.67 Gastroenterology
Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Abstract

Bukh, Jens

Copenhagen University Hospital 11/25/2010 11.67 Gastroenterology
Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α. Abstract

Lemon, Stanley M

The University of North Carolina at Chapel Hill 11/04/2010 11.67 Gastroenterology
Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus. Abstract

Rehermann, Barbara

National Institutes of Health 10/30/2010 11.67 Gastroenterology
Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses. Abstract

Liang, T Jake

National Institutes of Health 09/17/2010 11.67 Gastroenterology
S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders. Abstract

Maehara, Yoshihiko

Kyushu University 08/12/2010 11.67 Gastroenterology
Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Abstract

Sulkowski, Mark S

Johns Hopkins University School of Medicine 06/27/2010 11.67 Gastroenterology
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1. Abstract

McHutchison, John G

Duke University Medical Center 06/02/2010 11.67 Gastroenterology
An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Abstract

Baumert, Thomas F

Inserm, U748, Strasbourg 06/02/2010 11.67 Gastroenterology
Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Abstract

McHutchison, John G

Duke University Medical Center 04/24/2010 11.67 Gastroenterology
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Abstract

Chung, Raymond T

Harvard Medical School 03/12/2010 11.67 Gastroenterology
Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner. Abstract

McHutchison, John G

Duke University Medical Center 02/19/2010 11.67 Gastroenterology
Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Abstract

Pietschmann, Thomas

Centre for Experimental and Clinical Infection Research 02/10/2010 11.67 Gastroenterology
Glucocorticosteroids increase cell entry by hepatitis C virus. Abstract

Wedemeyer, Heiner

Hannover Medical School 02/02/2010 11.67 Gastroenterology
Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Abstract

Zeuzem, Stefan

J.W. Goethe-University Hospital 12/16/2009 11.67 Gastroenterology
Resistance to direct antiviral agents in patients with hepatitis C virus infection. Abstract

Pawlotsky, Jean-Michel

Department of Virology, Hôpital Henri Mondor, Université Paris-Est Créteil 12/04/2009 11.67 Gastroenterology
Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Abstract

McKeating, Jane A

University of Birmingham 11/26/2009 11.67 Gastroenterology
Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner. Abstract

Colombo, Massimo

University of Milan 09/18/2009 11.67 Gastroenterology
Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Abstract

Rehermann, Barbara

National Institutes of Health 09/10/2009 11.67 Gastroenterology
Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Abstract

Lemon, Stanley M

The University of North Carolina at Chapel Hill 07/24/2009 11.67 Gastroenterology
Visualizing hepatitis C virus infections in human liver by two-photon microscopy. Abstract

Liang, T Jake

National Institutes of Health 04/23/2009 11.67 Gastroenterology
Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Abstract

Colombo, Massimo

University of Milan 01/29/2009 11.67 Gastroenterology
A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Abstract

Colombo, Massimo

University of Milan 01/22/2009 11.67 Gastroenterology
Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Abstract

Perelson, Alan S

Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545 01/01/2009 11.67 Gastroenterology
A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease. Abstract

Thimme, Robert

University of Freiburg 12/13/2008 11.67 Gastroenterology
Analysis of CD8+ T-cell-mediated inhibition of hepatitis C virus replication using a novel immunological model. Abstract

Perelson, Alan S

Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545 04/01/2014 11.66 Hepatology (Baltimore, Md.)
Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients. Abstract

McKeating, Jane A

University of Birmingham 02/25/2014 11.66 Hepatology (Baltimore, Md.)
Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner. Abstract

Pietschmann, Thomas

Centre for Experimental and Clinical Infection Research 02/10/2014 11.66 Hepatology (Baltimore, Md.)
Isolate-dependent use of claudins for cell entry by hepatitis C virus. Abstract

McKeating, Jane A

University of Birmingham 12/18/2013 11.66 Hepatology (Baltimore, Md.)
Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication. Abstract

Chung, Raymond T

Harvard Medical School 11/22/2013 11.66 Hepatology (Baltimore, Md.)
Human immunodeficiency virus and liver disease forum 2012. Abstract

Pietschmann, Thomas

Centre for Experimental and Clinical Infection Research 11/18/2013 11.66 Hepatology (Baltimore, Md.)
Cell entry, efficient RNA replication, and production of infectious hepatitis C virus progeny in mouse liver-derived cells. Abstract

Rehermann, Barbara

National Institutes of Health 09/30/2013 11.66 Hepatology (Baltimore, Md.)
Innate immune responses in hepatitis C virus-exposed healthcare workers who do not develop acute infection. Abstract

Kato, Nobuyuki

Okayama University Graduate School of Medicine 08/19/2013 11.66 Hepatology (Baltimore, Md.)
Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin. Abstract

Bukh, Jens

Copenhagen University Hospital 08/07/2013 11.66 Hepatology (Baltimore, Md.)
Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies. Abstract

El-Serag, Hashem B

Baylor College of Medicine 07/01/2013 11.66 Hepatology (Baltimore, Md.)
Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Abstract

El-Serag, Hashem B

Baylor College of Medicine 03/14/2013 11.66 Hepatology (Baltimore, Md.)
Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Abstract

Kumada, Hiromitsu

Toranomon Hospital 03/06/2013 11.66 Hepatology (Baltimore, Md.)
Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Abstract

Kumada, Hiromitsu

Toranomon Hospital 12/05/2012 11.66 Hepatology (Baltimore, Md.)
Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis. Abstract

Rehermann, Barbara

National Institutes of Health 11/19/2012 11.66 Hepatology (Baltimore, Md.)
IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Abstract

Rehermann, Barbara

National Institutes of Health 10/14/2012 11.66 Hepatology (Baltimore, Md.)
B cell homeostasis in chronic hepatitis C virus-related mixed cryoglobulinemia is maintained through naïve B cell apoptosis. Abstract

Bartenschlager, Ralf

Heidelberg University 10/14/2012 11.66 Hepatology (Baltimore, Md.)
Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication. Abstract

Pineda, Juan A

Hospital Universitario de Valme 09/11/2012 11.66 Hepatology (Baltimore, Md.)
Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients. Abstract

Perelson, Alan S

Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545 02/15/2012 11.66 Hepatology (Baltimore, Md.)
Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Abstract

Kumada, Hiromitsu

Toranomon Hospital 01/30/2012 11.66 Hepatology (Baltimore, Md.)
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Abstract

Colombo, Massimo

University of Milan 01/03/2012 11.66 Hepatology (Baltimore, Md.)
Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Abstract

Rice, Charles M

The Rockefeller University 12/06/2011 11.66 Hepatology (Baltimore, Md.)
Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells. Abstract

He, Xianghuo

Fudan University 12/06/2011 11.66 Hepatology (Baltimore, Md.)
Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. Abstract

Rehermann, Barbara

National Institutes of Health 11/14/2011 11.66 Hepatology (Baltimore, Md.)
Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. Abstract

Colombo, Massimo

University of Milan 08/19/2011 11.66 Hepatology (Baltimore, Md.)
Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Abstract

Liang, T Jake

National Institutes of Health 08/11/2011 11.66 Hepatology (Baltimore, Md.)
Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees. Abstract

Chayama, Kazuaki

Hiroshima University 08/02/2011 11.66 Hepatology (Baltimore, Md.)
Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus. Abstract

Chayama, Kazuaki

Hiroshima University 08/02/2011 11.66 Hepatology (Baltimore, Md.)
Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo. Abstract

Ray, Ranjit

Saint Louis University 07/25/2011 11.66 Hepatology (Baltimore, Md.)
Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes. Abstract

McHutchison, John G

Duke University Medical Center 07/21/2011 11.66 Hepatology (Baltimore, Md.)
Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Abstract

Nguyen, Mindie H

Pacific Health Foundation 05/27/2011 11.66 Hepatology (Baltimore, Md.)
Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection. Abstract

Perelson, Alan S

Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545 05/02/2011 11.66 Hepatology (Baltimore, Md.)
Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Abstract

Pawlotsky, Jean-Michel

Department of Virology, Hôpital Henri Mondor, Université Paris-Est Créteil 04/26/2011 11.66 Hepatology (Baltimore, Md.)
Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Abstract

Dore, Gregory J

The University of New South Wales 04/11/2011 11.66 Hepatology (Baltimore, Md.)
Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. Abstract

Chayama, Kazuaki

Hiroshima University 04/11/2011 11.66 Hepatology (Baltimore, Md.)
Impact of radiation and hepatitis virus infection on risk of hepatocellular carcinoma. Abstract

McHutchison, John G

Duke University Medical Center 01/21/2011 11.66 Hepatology (Baltimore, Md.)
Hepatitis C pharmacogenetics: state of the art in 2010. Abstract

He, Xianghuo

Fudan University 01/03/2011 11.66 Hepatology (Baltimore, Md.)
Acetylcholinesterase, a key prognostic predictor for hepatocellular carcinoma, suppresses cell growth and induces chemosensitization. Abstract

El-Serag, Hashem B

Baylor College of Medicine 12/13/2010 11.66 Hepatology (Baltimore, Md.)
Meeting vaccination quality measures for hepatitis A and B virus in patients with chronic hepatitis C infection. Abstract

He, Xianghuo

Fudan University 11/01/2010 11.66 Hepatology (Baltimore, Md.)
MicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. Abstract

Nguyen, Mindie H

Pacific Health Foundation 11/01/2010 11.66 Hepatology (Baltimore, Md.)
Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6. Abstract

Liang, T Jake

National Institutes of Health 10/26/2010 11.66 Hepatology (Baltimore, Md.)
Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Abstract

Kumada, Hiromitsu

Toranomon Hospital 08/04/2010 11.66 Hepatology (Baltimore, Md.)
Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Abstract

El-Serag, Hashem B

Baylor College of Medicine 07/01/2010 11.66 Hepatology (Baltimore, Md.)
Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Abstract

Fan, Jia

Fudan University 07/01/2010 11.66 Hepatology (Baltimore, Md.)
CD151 modulates expression of matrix metalloproteinase 9 and promotes neoangiogenesis and progression of hepatocellular carcinoma. Abstract

Ray, Ranjit

Saint Louis University 04/30/2010 11.66 Hepatology (Baltimore, Md.)
Hepatitis C virus core protein interacts with fibrinogen-beta and attenuates cytokine stimulated acute-phase response. Abstract

Baumert, Thomas F

Inserm, U748, Strasbourg 04/07/2010 11.66 Hepatology (Baltimore, Md.)
Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Abstract

Marcellin, Patrick

Beaujon Hospital 04/07/2010 11.66 Hepatology (Baltimore, Md.)
Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Abstract

Pietschmann, Thomas

Centre for Experimental and Clinical Infection Research 11/05/2009 11.66 Hepatology (Baltimore, Md.)
Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. Abstract

Pineda, Juan A

Hospital Universitario de Valme 10/05/2009 11.66 Hepatology (Baltimore, Md.)
Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Abstract

Chung, Raymond T

Harvard Medical School 10/05/2009 11.66 Hepatology (Baltimore, Md.)
Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Abstract

Kato, Nobuyuki

Okayama University Graduate School of Medicine 09/02/2009 11.66 Hepatology (Baltimore, Md.)
Oxidative stress induces anti-hepatitis C virus status via the activation of extracellular signal-regulated kinase. Abstract

Zeuzem, Stefan

J.W. Goethe-University Hospital 08/04/2009 11.66 Hepatology (Baltimore, Md.)
Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Abstract

Pawlotsky, Jean-Michel

Department of Virology, Hôpital Henri Mondor, Université Paris-Est Créteil 05/04/2009 11.66 Hepatology (Baltimore, Md.)
Seroconversion to hepatitis C virus alternate reading frame protein during acute infection. Abstract

Kumada, Hiromitsu

Toranomon Hospital 03/03/2009 11.66 Hepatology (Baltimore, Md.)
Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Abstract

Fan, Jia

Fudan University 02/03/2009 11.66 Hepatology (Baltimore, Md.)
Capn4 overexpression underlies tumor invasion and metastasis after liver transplantation for hepatocellular carcinoma. Abstract

Fan, Jia

Fudan University 02/03/2009 11.66 Hepatology (Baltimore, Md.)
Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Abstract

Bukh, Jens

Copenhagen University Hospital 02/03/2009 11.66 Hepatology (Baltimore, Md.)
Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Abstract

Rehermann, Barbara

National Institutes of Health 01/05/2009 11.66 Hepatology (Baltimore, Md.)
Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. Abstract

Bartenschlager, Ralf

Heidelberg University 01/04/2012 10.96 FEMS microbiology reviews
Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. Abstract

Baumert, Thomas F

Inserm, U748, Strasbourg 05/25/2010 10.35 Trends in molecular medicine
Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. Abstract

Zeuzem, Stefan

J.W. Goethe-University Hospital 02/21/2014 10.33 EMBO molecular medicine
Emerging therapies for the treatment of hepatitis C. Abstract

Wedemeyer, H

Hannover Medical School 11/07/2013 10.11 Gut
Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. Abstract

Chayama, Kazuaki

Hiroshima University 01/15/2013 10.11 Gut
Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice. Abstract

Marcellin, Patrick

Beaujon Hospital 03/02/2012 10.11 Gut
Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1. Abstract

Thimme, Robert

University of Freiburg 08/28/2011 10.11 Gut
T cell responses in hepatitis C: the good, the bad and the unconventional. Abstract

Chayama, Kazuaki

Hiroshima University 11/10/2010 10.11 Gut
HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Abstract

Marcellin, Patrick

Beaujon Hospital 09/21/2010 10.11 Gut
Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Abstract

Cacoub, Patrice

Groupe Hospitalier Pitié-Salpétrière 09/14/2010 10.11 Gut
Presentation and outcome of gastrointestinal involvement in hepatitis C virus-related systemic vasculitis: a case-control study from a single-centre cohort of 163 patients. Abstract

Fan, Jia

Fudan University 05/04/2010 10.11 Gut
High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Abstract

Marcellin, P

INSERM, U773, Centre de Recherche Bichat-Beaujon CRB3, Paris 08/10/2009 10.11 Gut
Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Abstract

Pineda, J A

Unidad de Enfermedades Infecciosas. Hospital Universitario de Valme. Avenida de Bellavista, Sevilla 07/21/2009 10.11 Gut
Insulin resistance is associated with liver stiffness in HIV/HCV co-infected patients. Abstract

Marcellin, P

INSERM, U773, Centre de Recherche Bichat-Beaujon CRB3, Paris 12/11/2008 10.11 Gut
Gene expression and hepatitis C virus infection. Abstract

Cacoub, Patrice

Groupe Hospitalier Pitié-Salpétrière 05/03/2010 9.90 Blood
Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Abstract

McKeating, Jane A

University of Birmingham 10/06/2008 9.90 Blood
Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells. Abstract

Rice, Charles M

The Rockefeller University 05/20/2013 9.81 Proceedings of the National Academy of Sciences of the United States of America
Ultrastructural analysis of hepatitis C virus particles. Abstract

Perelson, Alan S

Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545 02/19/2013 9.81 Proceedings of the National Academy of Sciences of the United States of America
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Abstract

Lemon, Stanley M

The University of North Carolina at Chapel Hill 12/17/2012 9.81 Proceedings of the National Academy of Sciences of the United States of America
Competing and noncompeting activities of miR-122 and the 5' exonuclease Xrn1 in regulation of hepatitis C virus replication. Abstract

Bukh, Jens

Copenhagen University Hospital 11/14/2012 9.81 Proceedings of the National Academy of Sciences of the United States of America
Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system. Abstract

Bukh, Jens

Copenhagen University Hospital 03/30/2012 9.81 Proceedings of the National Academy of Sciences of the United States of America
Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. Abstract

Lemon, Stanley M

The University of North Carolina at Chapel Hill 01/03/2012 9.81 Proceedings of the National Academy of Sciences of the United States of America
Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex. Abstract

Lemon, Stanley M

The University of North Carolina at Chapel Hill 06/20/2011 9.81 Proceedings of the National Academy of Sciences of the United States of America
Acute hepatitis A virus infection is associated with a limited type I interferon response and persistence of intrahepatic viral RNA. Abstract

Bukh, Jens

Copenhagen University Hospital 03/07/2011 9.81 Proceedings of the National Academy of Sciences of the United States of America
MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR. Abstract

Cheng, Ann-Lii

National Taiwan University Hospital 09/12/2013 9.26 Journal of hepatology
Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy. Abstract

Bartenschlager, Ralf

Heidelberg University 08/08/2013 9.26 Journal of hepatology
Interferon-stimulated genes and their role in controlling hepatitis C virus. Abstract

Chung, Raymond T

Harvard Medical School 07/02/2013 9.26 Journal of hepatology
The AMPK-related kinase SNARK regulates hepatitis C virus replication and pathogenesis through enhancement of TGF-β signaling. Abstract

Zeuzem, Stefan

J.W. Goethe-University Hospital 03/27/2013 9.26 Journal of hepatology
Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. Abstract

Colombo, Massimo

University of Milan 03/23/2013 9.26 Journal of hepatology
The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. Abstract

Colombo, Massimo

University of Milan 02/26/2013 9.26 Journal of hepatology
Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis. Abstract

McKeating, Jane A

University of Birmingham 01/23/2013 9.26 Journal of hepatology
Early infection events highlight the limited transmissibility of hepatitis C virus in vitro. Abstract

Kumada, Hiromitsu

Toranomon Hospital 11/23/2012 9.26 Journal of hepatology
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. Abstract

Zeuzem, Stefan

J.W. Goethe-University Hospital 11/05/2012 9.26 Journal of hepatology
Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. Abstract

Zeuzem, Stefan

J.W. Goethe-University Hospital 10/24/2012 9.26 Journal of hepatology
Perspectives and challenges of interferon-free therapy for chronic hepatitis C. Abstract

Baumert, Thomas F

Inserm, U748, Strasbourg 10/04/2012 9.26 Journal of hepatology
Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges. Abstract

Maehara, Yoshihiko

Kyushu University 08/25/2012 9.26 Journal of hepatology
Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. Abstract

He, Xiaoshun

Sun Yat-sen University 07/20/2012 9.26 Journal of hepatology
Living donor vs. deceased donor liver transplantation for patients with hepatitis C virus-related diseases. Abstract

Dore, Gregory J

The University of New South Wales 07/14/2012 9.26 Journal of hepatology
Case definitions for acute hepatitis C virus infection: a systematic review. Abstract

Llovet, Josep M

Mount Sinai School of Medicine 06/19/2012 9.26 Journal of hepatology
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. Abstract

Pawlotsky, Jean-Michel

Department of Virology, Hôpital Henri Mondor, Université Paris-Est Créteil 05/18/2012 9.26 Journal of hepatology
Hepatitis C virus (HCV) protein expression enhances hepatic fibrosis in HCV transgenic mice exposed to a fibrogenic agent. Abstract

Thimme, Robert

University of Freiburg 03/14/2012 9.26 Journal of hepatology
Low perforin expression of early differentiated HCV-specific CD8+ T cells limits their hepatotoxic potential. Abstract

Llovet, Josep M

Mount Sinai School of Medicine 02/06/2012 9.26 Journal of hepatology
Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. Abstract

Perelson, Alan S

Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545 01/13/2012 9.26 Journal of hepatology
Understanding silibinin's modes of action against HCV using viral kinetic modeling. Abstract

Cheng, Ann-Lii

National Taiwan University Hospital 01/13/2012 9.26 Journal of hepatology
Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study. Abstract

McKeating, Jane A

University of Birmingham 12/16/2011 9.26 Journal of hepatology
A dual role for hypoxia inducible factor-1α in the hepatitis C virus lifecycle and hepatoma migration. Abstract

Pineda, Juan A

Hospital Universitario de Valme 12/13/2011 9.26 Journal of hepatology
Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. Abstract

Marcellin, Patrick

Beaujon Hospital 09/25/2011 9.26 Journal of hepatology
IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. Abstract

Chung, Raymond T

Harvard Medical School 08/31/2011 9.26 Journal of hepatology
A functional genomic screen reveals novel host genes that mediate interferon-alpha's effects against hepatitis C virus. Abstract

El-Serag, Hashem B

Baylor College of Medicine 07/12/2011 9.26 Journal of hepatology
Gaps in the achievement of effectiveness of HCV treatment in national VA practice. Abstract

Baumert, Thomas F

Inserm, U748, Strasbourg 05/14/2011 9.26 Journal of hepatology
A first step towards a mouse model for hepatitis C virus infection containing a human immune system. Abstract

Prins, Maria

University of California 04/13/2011 9.26 Journal of hepatology
Hepatitis C in the general population of various ethnic origins living in the Netherlands: should non-Western migrants be screened? Abstract

Llovet, Josep M

Mount Sinai School of Medicine 04/13/2011 9.26 Journal of hepatology
Gene-expression signature of vascular invasion in hepatocellular carcinoma. Abstract

Zeuzem, Stefan

J.W. Goethe-University Hospital 03/25/2011 9.26 Journal of hepatology
IL28B single nucleotide polymorphisms in the treatment of hepatitis C. Abstract

Zeuzem, Stefan

J.W. Goethe-University Hospital 02/24/2011 9.26 Journal of hepatology
Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. Abstract

Cacoub, Patrice

Groupe Hospitalier Pitié-Salpétrière 02/18/2011 9.26 Journal of hepatology
Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. Abstract

Chayama, Kazuaki

Hiroshima University 02/04/2011 9.26 Journal of hepatology
IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. Abstract

Wedemeyer, Heiner

Hannover Medical School 01/12/2011 9.26 Journal of hepatology
Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. Abstract

Chung, Raymond T

Harvard Medical School 12/13/2010 9.26 Journal of hepatology
IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. Abstract

Chayama, Kazuaki

Hiroshima University 11/29/2010 9.26 Journal of hepatology
ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo. Abstract

Zeuzem, Stefan

J.W. Goethe-University Hospital 11/23/2010 9.26 Journal of hepatology
Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. Abstract

Chayama, Kazuaki

Hiroshima University 11/18/2010 9.26 Journal of hepatology
A single nucleotide polymorphism in activated Cdc42 associated tyrosine kinase 1 influences the interferon therapy in hepatitis C patients. Abstract

Baumert, Thomas F

Inserm, U748, Strasbourg 11/11/2010 9.26 Journal of hepatology
Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. Abstract

Thimme, Robert

University of Freiburg 11/09/2010 9.26 Journal of hepatology
Potential of immunotherapy for hepatocellular carcinoma. Abstract

Chayama, Kazuaki

Hiroshima University 10/26/2010 9.26 Journal of hepatology
Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice. Abstract

Dore, Gregory J

The University of New South Wales 10/23/2010 9.26 Journal of hepatology
Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006. Abstract

Chung, Raymond T

Harvard Medical School 09/29/2010 9.26 Journal of hepatology
HIV infection increases HCV-induced hepatocyte apoptosis. Abstract

Chayama, Kazuaki

Hiroshima University 09/19/2010 9.26 Journal of hepatology
Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. Abstract

Sulkowski, Mark S

Johns Hopkins University School of Medicine 08/21/2010 9.26 Journal of hepatology
Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patients. Abstract

Fan, Jia

Fudan University 07/15/2010 9.26 Journal of hepatology
PEBP1 downregulation is associated to poor prognosis in HCC related to hepatitis B infection. Abstract

Chayama, Kazuaki

Hiroshima University 05/31/2010 9.26 Journal of hepatology
Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. Abstract

Cacoub, Patrice

Groupe Hospitalier Pitié-Salpétrière 04/18/2010 9.26 Journal of hepatology
Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection. Abstract

Cheng, Ann-Lii

National Taiwan University Hospital 03/30/2010 9.26 Journal of hepatology
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. Abstract

Zeuzem, Stefan

J.W. Goethe-University Hospital 03/15/2010 9.26 Journal of hepatology
Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. Abstract

Maehara, Yoshihiko

Kyushu University 03/04/2010 9.26 Journal of hepatology
Mutations in hepatitis C virus genotype 1b and the sensitivity of interferon-ribavirin therapy after liver transplantation. Abstract

Marcellin, Patrick

Beaujon Hospital 03/04/2010 9.26 Journal of hepatology
Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. Abstract

Cheng, Ann-Lii

National Taiwan University Hospital 10/23/2009 9.26 Journal of hepatology
Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. Abstract

Chayama, Kazuaki

Hiroshima University 09/23/2009 9.26 Journal of hepatology
Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice. Abstract

Llovet, Josep M

Mount Sinai School of Medicine 06/12/2009 9.26 Journal of hepatology
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. Abstract

Chung, Raymond T

Harvard Medical School 02/14/2009 9.26 Journal of hepatology
Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection. Abstract

Cheng, Ann-Lii

National Taiwan University Hospital 12/25/2008 9.26 Journal of hepatology
The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma. Abstract

Chung, Raymond T

Harvard Medical School 12/03/2008 9.26 Journal of hepatology
Treatment failure in hepatitis C: mechanisms of non-response. Abstract

Baumert, Thomas F

Inserm, U748, Strasbourg 11/05/2008 9.26 Journal of hepatology
EWI-2wint--a host cell factor inhibiting hepatitis C virus entry. Abstract

McHutchison, John G

Duke University Medical Center 11/04/2008 9.26 Journal of hepatology
Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. Abstract

05/20/2009 9.23 Human reproduction update
Female contraception over 40. Abstract

Pineda, Juan A

Hospital Universitario de Valme 08/14/2013 9.15 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Risk of liver decompensation among HIV/hepatitis C virus-coinfected individuals with advanced fibrosis: implications for the timing of therapy. Abstract

Prins, Maria

University of California 07/25/2013 9.15 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Abstract

Dore, Gregory J

The University of New South Wales 05/31/2013 9.15 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements. Abstract

Pineda, Juan A

Hospital Universitario de Valme 04/10/2013 9.15 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Chronic hepatitis E in HIV patients: rapid progression to cirrhosis and response to oral ribavirin. Abstract

Soriano, Vincent

Hospital Carlos III 10/22/2012 9.15 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Hepatitis C therapy: highlights from the 2012 annual meeting of the European Association for the Study of the Liver. Abstract

Pineda, Juan A

Hospital Universitario de Valme 09/05/2012 9.15 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Abstract

Pineda, Juan A

Hospital Universitario de Valme 09/05/2012 9.15 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain. Abstract

Soriano, Vincent

Hospital Carlos III 10/22/2010 9.15 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Abstract

Soriano, Vincent

Hospital Carlos III 10/14/2009 9.15 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients. Abstract

Pineda, Juan A

Hospital Universitario de Valme 09/28/2009 9.15 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression. Abstract

Zeuzem, Stefan

J.W. Goethe-University Hospital 01/08/2009 9.15 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
New therapies for hepatitis C virus infection. Abstract

Lemon, Stanley M

The University of North Carolina at Chapel Hill 05/23/2013 9.13 PLoS pathogens
Class A scavenger receptor 1 (MSR1) restricts hepatitis C virus replication by mediating toll-like receptor 3 recognition of viral RNAs produced in neighboring cells. Abstract

Pietschmann, Thomas

Centre for Experimental and Clinical Infection Research 05/02/2013 9.13 PLoS pathogens
hepatitis c Virus p7 is critical for capsid assembly and envelopment. Abstract

Bukh, Jens

Copenhagen University Hospital 03/28/2013 9.13 PLoS pathogens
Productive homologous and non-homologous recombination of hepatitis C virus in cell culture. Abstract

Bartenschlager, Ralf

Heidelberg University 12/06/2012 9.13 PLoS pathogens
Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication. Abstract

Thimme, Robert

University of Freiburg 11/29/2012 9.13 PLoS pathogens
Rapid antigen processing and presentation of a protective and immunodominant HLA-B*27-restricted hepatitis C virus-specific CD8+ T-cell epitope. Abstract

Perelson, Alan S

Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545 08/23/2012 9.13 PLoS pathogens
Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. Abstract

Pietschmann, Thomas

Centre for Experimental and Clinical Infection Research 07/26/2012 9.13 PLoS pathogens
MAP-kinase regulated cytosolic phospholipase A2 activity is essential for production of infectious hepatitis C virus particles. Abstract

Wedemeyer, Heiner

Hannover Medical School 05/19/2011 9.13 PLoS pathogens
Dual function of the NK cell receptor 2B4 (CD244) in the regulation of HCV-specific CD8+ T cells. Abstract

Pietschmann, Thomas

Centre for Experimental and Clinical Infection Research 04/28/2011 9.13 PLoS pathogens
Completion of hepatitis C virus replication cycle in heterokaryons excludes dominant restrictions in human non-liver and mouse liver cell lines. Abstract

Pietschmann, Thomas

Centre for Experimental and Clinical Infection Research 07/01/2010 9.13 PLoS pathogens
Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. Abstract

Thimme, Robert

University of Freiburg 06/10/2010 9.13 PLoS pathogens
Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. Abstract

Bartenschlager, Ralf

Heidelberg University 08/14/2009 9.13 PLoS pathogens
Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. Abstract

Bartenschlager, Ralf

Heidelberg University 06/12/2009 9.13 PLoS pathogens
Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. Abstract

Cacoub, Patrice

Groupe Hospitalier Pitié-Salpétrière 04/20/2013 8.73 Annals of the rheumatic diseases
Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Abstract

Cacoub, Patrice

Groupe Hospitalier Pitié-Salpétrière 09/27/2010 8.73 Annals of the rheumatic diseases
Surrogate markers of B cell non-Hodgkin's lymphoma in patients with hepatitis C virus-related cryoglobulinaemia vasculitis. Abstract

Cacoub, P

Laboratoire de Biologie et Thérapeutique des Pathologies Immunitaires, Centre National de la Recherche Sientifique, Universite Pierre et Marrie C… 04/23/2008 8.73 Annals of the rheumatic diseases
The B lymphocyte stimulator receptor-ligand system in hepatitis C virus-induced B cell clonal disorders. Abstract

Cacoub, P

Laboratoire de Biologie et Thérapeutique des Pathologies Immunitaires, Centre National de la Recherche Sientifique, Universite Pierre et Marrie C… 03/28/2008 8.73 Annals of the rheumatic diseases
Serum-free light chain assessment in hepatitis C virus-related lymphoproliferative disorders. Abstract

He, Xianghuo

Fudan University 12/03/2013 8.19 Cell research
Amplification of MPZL1/PZR promotes tumor cell migration through Src-mediated phosphorylation of cortactin in hepatocellular carcinoma. Abstract

Dore, Gregory J

The University of New South Wales 07/02/2013 8.10 Nature reviews. Gastroenterology & hepatology
Epidemiology and natural history of HCV infection. Abstract

Chayama, Kazuaki

Hiroshima University 05/29/2012 8.10 Nature reviews. Gastroenterology & hepatology
Genetics of IL28B and HCV--response to infection and treatment. Abstract

Zeuzem, Stefan

J.W. Goethe-University Hospital 04/05/2011 8.10 Nature reviews. Gastroenterology & hepatology
A new standard of care for the treatment of chronic HCV infection. Abstract

Dore, Gregory J

The University of New South Wales 03/22/2011 8.10 Nature reviews. Gastroenterology & hepatology
Treatment of acute HCV infection. Abstract

Marcellin, Patrick

Beaujon Hospital 08/28/2009 8.10 Nature reviews. Gastroenterology & hepatology
Hepatitis C: The role of new interferons in the era of STAT-C. Abstract

Cacoub, Patrice

Groupe Hospitalier Pitié-Salpétrière 06/01/2011 7.87 Arthritis and rheumatism
Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. Abstract

Cacoub, Patrice

Groupe Hospitalier Pitié-Salpétrière 12/16/2009 7.87 Arthritis and rheumatism
Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Abstract

Cacoub, Patrice

Groupe Hospitalier Pitié-Salpétrière 08/11/2009 7.87 Arthritis and rheumatism
Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients. Abstract

Fan, Jia

Fudan University 06/18/2012 7.86 Cancer research
CXCR6 upregulation contributes to a proinflammatory tumor microenvironment that drives metastasis and poor patient outcomes in hepatocellular carcinoma. Abstract

Couch, Fergus J

Mayo Clinic College of Medicine 02/13/2012 7.86 Cancer research
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Abstract

Couch, Fergus J

Mayo Clinic College of Medicine 08/15/2011 7.86 Cancer research
Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Abstract

Pawlotsky, Jean-Michel

Department of Virology, Hôpital Henri Mondor, Université Paris-Est Créteil 06/08/2010 7.86 Cancer research
Downregulation of Gadd45beta expression by hepatitis C virus leads to defective cell cycle arrest. Abstract

Ray, Ranjit

Saint Louis University 08/04/2011 7.80 Science translational medicine
Progress toward development of a hepatitis C vaccine with broad shoulders. Abstract

Perelson, Alan S

Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545 05/06/2010 7.80 Science translational medicine
Rapid emergence of protease inhibitor resistance in hepatitis C virus. Abstract

Rice, Charles M

The Rockefeller University 04/07/2010 7.80 Science translational medicine
Antisense gets a grip on miR-122 in chimpanzees. Abstract

Llovet, Josep M

Mount Sinai School of Medicine 07/18/2012 7.74 Clinical cancer research : an official journal of the American Association for Cancer Research
Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Abstract

Cheng, Ann-Lii

National Taiwan University Hospital 05/23/2012 7.74 Clinical cancer research : an official journal of the American Association for Cancer Research
Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy. Abstract

Fan, Jia

Fudan University 08/08/2011 7.74 Clinical cancer research : an official journal of the American Association for Cancer Research
Autophagy activation in hepatocellular carcinoma contributes to the tolerance of oxaliplatin via reactive oxygen species modulation. Abstract

Cheng, Ann-Lii

National Taiwan University Hospital 09/30/2010 7.74 Clinical cancer research : an official journal of the American Association for Cancer Research
Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Abstract

Llovet, Josep M

Mount Sinai School of Medicine 08/16/2010 7.74 Clinical cancer research : an official journal of the American Association for Cancer Research
New strategies in hepatocellular carcinoma: genomic prognostic markers. Abstract

Cheng, Ann-Lii

National Taiwan University Hospital 09/08/2009 7.74 Clinical cancer research : an official journal of the American Association for Cancer Research
Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma. Abstract

Fan, Jia

Fudan University 08/25/2009 7.74 Clinical cancer research : an official journal of the American Association for Cancer Research
CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery. Abstract

Fan, Jia

Fudan University 10/01/2011 7.45 Autophagy
Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. Abstract

Fan, Jia

Fudan University 04/19/2009 7.45 Autophagy
Prognostic significance of Beclin 1-dependent apoptotic activity in hepatocellular carcinoma. Abstract

Rice, Charles M

The Rockefeller University 10/16/2009 7.36 EMBO reports
Towards a small animal model for hepatitis C. Abstract

Chayama, Kazuaki

Hiroshima University 07/30/2013 7.28 The American journal of gastroenterology
A translational study of resistance emergence using sequential direct-acting antiviral agents for hepatitis C using ultra-deep sequencing. Abstract

Kumada, Hiromitsu

Toranomon Hospital 10/18/2011 7.28 The American journal of gastroenterology
Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma. Abstract

El-Serag, Hashem B

Baylor College of Medicine 11/09/2010 7.28 The American journal of gastroenterology
Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. Abstract

McHutchison, John G

Duke University Medical Center 10/05/2010 7.28 The American journal of gastroenterology
IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. Abstract

Nguyen, Mindie H

Pacific Health Foundation 11/10/2009 7.28 The American journal of gastroenterology
Similar treatment response to peginterferon and ribavirin in Asian and Caucasian patients with chronic hepatitis C. Abstract

McKeating, Jane A

University of Birmingham 03/06/2012 7.20 Reviews in medical virology
Hepatitis C virus entry: beyond receptors. Abstract

Chung, Raymond T

Harvard Medical School 11/12/2013 7.05 Seminars in liver disease
HCV and host lipids: an intimate connection. Abstract

Colombo, Massimo

University of Milan 03/01/2013 7.05 Seminars in liver disease
Shaping the future management of hepatocellular carcinoma. Abstract

Soriano, Vincent

Hospital Carlos III 07/03/2012 7.05 Seminars in liver disease
Management and treatment of chronic hepatitis C in HIV patients. Abstract

Dore, Gregory J

The University of New South Wales 12/21/2011 7.05 Seminars in liver disease
What is killing people with hepatitis C virus infection? Abstract

Chung, Raymond T

Harvard Medical School 12/21/2011 7.05 Seminars in liver disease
The impact of human gene polymorphisms on HCV infection and disease outcome. Abstract

Lemon, Stanley M

The University of North Carolina at Chapel Hill 10/19/2010 7.05 Seminars in liver disease
Hepatitis A and hepatitis C viruses: divergent infection outcomes marked by similarities in induction and evasion of interferon responses. Abstract

Bartenschlager, Ralf

Heidelberg University 10/19/2010 7.05 Seminars in liver disease
New insights into structure and replication of the hepatitis C virus and clinical implications. Abstract

Lemon, Stanley M

The University of North Carolina at Chapel Hill 09/15/2009 6.86 Current opinion in pharmacology
Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities. Abstract

Cacoub, Patrice

Groupe Hospitalier Pitié-Salpétrière 11/09/2013 6.62 Autoimmunity reviews
Serum biomarker signature identifies patients with B-cell non-Hodgkin lymphoma associated with cryoglobulinemia vasculitis in chronic HCV infection. Abstract

Nguyen, Mindie H

Pacific Health Foundation 12/17/2013 6.53 Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Increased long-term survival among patients with hepatocellular carcinoma after implementation of Model for End-stage Liver Disease score. Abstract

El-Serag, Hashem B

Baylor College of Medicine 08/23/2013 6.53 Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Many patients with interleukin 28B genotypes associated with response to therapy are ineligible for treatment because of comorbidities. Abstract

Chung, Raymond T

Harvard Medical School 07/18/2013 6.53 Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Direct-acting antiviral agents and the path to interferon independence. Abstract

El-Serag, Hashem B

Baylor College of Medicine 10/04/2012 6.53 Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Abstract

Nguyen, Mindie H

Pacific Health Foundation 08/16/2012 6.53 Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Incidence of hepatocellular carcinoma among US patients with cirrhosis of viral or nonviral etiologies. Abstract

El-Serag, Hashem B

Baylor College of Medicine 12/07/2011 6.53 Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Determinants of serum alpha-fetoprotein levels in hepatitis C-infected patients. Abstract

El-Serag, Hashem B

Baylor College of Medicine 08/04/2011 6.53 Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Level of α-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. Abstract

Prins, Maria

University of California 05/20/2011 6.53 Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
No impact of hepatitis C virus infection on mortality among drug users during the first decade after seroconversion. Abstract

Cristofanilli, M

Dubai Hospital 07/05/2010 6.43 Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Abstract

Wedemeyer, Heiner

Hannover Medical School 10/23/2013 6.41 The Journal of infectious diseases
Compromised function of natural killer cells in acute and chronic viral hepatitis. Abstract

Rehermann, Barbara

National Institutes of Health 06/24/2013 6.41 The Journal of infectious diseases
Occupational exposure to hepatitis C virus: early T-cell responses in the absence of seroconversion in a longitudinal cohort study. Abstract

Chung, Raymond T

Harvard Medical School 02/07/2013 6.41 The Journal of infectious diseases
Pathogenesis of accelerated fibrosis in HIV/HCV co-infection. Abstract

Dore, Gregory J

The University of New South Wales 02/07/2013 6.41 The Journal of infectious diseases
Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. Abstract

Sulkowski, Mark S

Johns Hopkins University School of Medicine 02/07/2013 6.41 The Journal of infectious diseases
Current management of hepatitis C virus infection in patients with HIV co-infection. Abstract

Baumert, Thomas F

Inserm, U748, Strasbourg 01/18/2013 6.41 The Journal of infectious diseases
Hepatitis C virus envelope glycoprotein signatures are associated with treatment failure and modulation of viral entry and neutralization. Abstract

Dore, Gregory J

The University of New South Wales 09/04/2012 6.41 The Journal of infectious diseases
Impaired hepatitis C virus (HCV)-specific interferon-γ responses in individuals with HIV who acquire HCV infection: correlation with CD4(+) T-cell counts. Abstract

Wedemeyer, Heiner

Hannover Medical School 03/29/2012 6.41 The Journal of infectious diseases
Interferon α-stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1. Abstract

Thimme, Robert

University of Freiburg 02/20/2012 6.41 The Journal of infectious diseases
Differential antigen specificity of hepatitis C virus-specific interleukin 17- and interferon γ-producing CD8(+) T cells during chronic infection. Abstract

Rehermann, Barbara

National Institutes of Health 01/31/2012 6.41 The Journal of infectious diseases
Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. Abstract

Soriano, Vincent

Hospital Carlos III 12/09/2011 6.41 The Journal of infectious diseases
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes. Abstract

Zeuzem, Stefan

J.W. Goethe-University Hospital 07/27/2011 6.41 The Journal of infectious diseases
Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C. Abstract

Chung, Raymond T

Harvard Medical School 07/27/2011 6.41 The Journal of infectious diseases
Ceestatin, a novel small molecule inhibitor of hepatitis C virus replication, inhibits 3-hydroxy-3-methylglutaryl-coenzyme A synthase. Abstract

Kumada, Hiromitsu

Toranomon Hospital 06/01/2011 6.41 The Journal of infectious diseases
IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. Abstract

Soriano, Vincent

Hospital Carlos III 05/19/2011 6.41 The Journal of infectious diseases
Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. Abstract

Pawlotsky, Jean-Michel

Department of Virology, Hôpital Henri Mondor, Université Paris-Est Créteil 10/04/2010 6.41 The Journal of infectious diseases
Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections. Abstract

Maehara, Y

Kyushu University 06/07/2011 6.39 American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
The impact of IL28B genetic variants on recurrent hepatitis C in liver transplantation: significant lessons from a dual graft case. Abstract

Nguyen, M H

Stanford University Medical Center 03/16/2009 6.39 American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Abstract

Pawlotsky, J-M

Institut National de la Santé et de la Recherche Médicale (INSERM), U955, Institut Mondor de Recherche Biomédicale, Créteil 10/29/2012 6.37 Oncogene
Hepatitis C virus-induced activation of β-catenin promotes c-Myc expression and a cascade of pro-carcinogenetic events. Abstract

Lemon, S M

The University of North Carolina at Chapel Hill 01/24/2011 6.37 Oncogene
Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Abstract

Chung, R T

Harvard Medical School 03/15/2010 6.37 Oncogene
Viral hepatocarcinogenesis. Abstract

Lemon, Stanley M

The University of North Carolina at Chapel Hill 08/07/2012 6.27 Seminars in immunopathology
Innate immune responses in hepatitis C virus infection. Abstract

Colombo, Massimo

University of Milan 07/22/2012 6.27 Seminars in immunopathology
Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. Abstract

Pineda, Juan A

Hospital Universitario de Valme 01/13/2014 6.25 AIDS (London, England)
HIV/hepatitis C virus-coinfected patients who achieved sustained virological response are still at risk of developing hepatocellular carcinoma. Abstract

Pineda, Juan A

Hospital Universitario de Valme 01/03/2014 6.25 AIDS (London, England)
Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection. Abstract

Pineda, Juan A

Hospital Universitario de Valme 10/07/2013 6.25 AIDS (London, England)
Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patients. Abstract

Soriano, Vicente

Hospital Universitario de Valme 08/01/2013 6.25 AIDS (London, England)
Liver stiffness predicts liver-related complications and mortality in HIV patients with chronic hepatitis C on antiretroviral therapy. Abstract

Resino, Salvador

Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid 07/01/2013 6.25 AIDS (London, England)
HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy. Abstract

Royal Derby Hospital 05/31/2013 6.25 AIDS (London, England)
Hepatitis-B virus infection predicts mortality of HIV and hepatitis C virus coinfected patients. Abstract

Resino, Salvador

Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid 12/17/2012 6.25 AIDS (London, England)
Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients. Abstract

Prins, Maria

University of California 10/25/2011 6.25 AIDS (London, England)
Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. Abstract

Resino, Salvador

Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid 08/04/2011 6.25 AIDS (London, England)
European mitochondrial DNA haplogroups and liver fibrosis in HIV and hepatitis C virus coinfected patients. Abstract

Prins, Maria

University of California 05/03/2011 6.25 AIDS (London, England)
The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. Abstract

Soriano, Vincent

Hospital Carlos III 05/03/2011 6.25 AIDS (London, England)
Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse. Abstract

Soriano, Vincent

Hospital Carlos III 03/18/2011 6.25 AIDS (London, England)
Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. Abstract

Resino, Salvador

Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid 08/03/2010 6.25 AIDS (London, England)
Hepatitis C virus infection is associated with endothelial dysfunction in HIV/hepatitis C virus coinfected patients. Abstract

Soriano, Vincent

Hospital Carlos III 04/27/2010 6.25 AIDS (London, England)
Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. Abstract

Sulkowski, Mark S

Johns Hopkins University School of Medicine 03/17/2010 6.25 AIDS (London, England)
Hepatic steatosis associated with increased central body fat by dual-energy X-ray absorptiometry and uncontrolled HIV in HIV/hepatitis C co-infected persons. Abstract

Prins, Maria

University of California 07/23/2009 6.25 AIDS (London, England)
Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. Abstract

Prins, M

Department of Experimental Virology, Center for Infection and Immunology Amsterdam (CINIMA), Academic Medical Center, Amsterdam 04/15/2010 6.15 Euro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin
Evaluation of a risk assessment questionnaire to assist hepatitis C screening in the general population. Abstract

Narod, Steven A

University of Toronto 07/19/2011 6.05 Cancer treatment reviews
Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review. Abstract

Resino, Salvador

Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid 01/08/2013 6.04 BMC medicine
Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. Abstract

Nguyen, M H

Stanford University Medical Center 11/19/2013 5.48 Alimentary pharmacology & therapeutics
Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Abstract

Wedemeyer, H

Hannover Medical School 11/10/2013 5.48 Alimentary pharmacology & therapeutics
Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir. Abstract

El-Serag, H B

Clinical Epidemiology and Outcomes Program 05/26/2013 5.48 Alimentary pharmacology & therapeutics
The association between serological and dietary vitamin D levels and hepatitis C-related liver disease risk differs in African American and white males. Abstract

Nguyen, M H

Stanford University Medical Center 04/05/2013 5.48 Alimentary pharmacology & therapeutics
Systematic review: Asian patients with chronic hepatitis C infection. Abstract

Nguyen, M H

Stanford University Medical Center 05/29/2011 5.48 Alimentary pharmacology & therapeutics
Systematic review: epidemiology of hepatitis C genotype 6 and its management. Abstract

Cacoub, P

Laboratoire de Biologie et Thérapeutique des Pathologies Immunitaires, Centre National de la Recherche Sientifique, Universite Pierre et Marrie C… 03/09/2009 5.48 Alimentary pharmacology & therapeutics
Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients. Abstract

McKeating, J A

University of Birmingham 11/20/2012 5.46 Cellular microbiology
Hepatoma polarization limits CD81 and hepatitis C virus dynamics. Abstract

Fan, Jia

Fudan University 08/07/2012 5.44 International journal of cancer. Journal international du cancer
Overexpression of HnRNP A1 promotes tumor invasion through regulating CD44v6 and indicates poor prognosis for hepatocellular carcinoma. Abstract

Kato, Naoya

Shandong University 12/21/2011 5.44 International journal of cancer. Journal international du cancer
Type 2 diabetes and hepatocellular carcinoma: a case-control study in patients with chronic hepatitis B. Abstract

Cheng, Ann-Lii

National Taiwan University Hospital 11/19/2011 5.44 International journal of cancer. Journal international du cancer
The emerging epidemic of estrogen-related cancers in young women in a developing Asian country. Abstract

Fan, Jia

Fudan University 04/20/2011 5.44 International journal of cancer. Journal international du cancer
Validity of plasma macrophage migration inhibitory factor for diagnosis and prognosis of hepatocellular carcinoma. Abstract

Chung, Raymond T

Harvard Medical School 07/03/2012 5.44 The Journal of pediatrics
Expected and actual case ascertainment and treatment rates for children infected with hepatitis C in Florida and the United States: epidemiologic evidence from statewide and nationwide surveys. Abstract

Cacoub, Patrice

Groupe Hospitalier Pitié-Salpétrière 10/25/2012 5.43 American journal of kidney diseases : the official journal of the National Kidney Foundation
Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. Abstract

Kumada, Hiromitsu

Toranomon Hospital 04/20/2009 5.43 The American journal of medicine
Necessities of interferon therapy in elderly patients with chronic hepatitis C. Abstract

Ray, Ranjit

Saint Louis University 12/18/2013 5.40 Journal of virology
Hepatitis C virus impairs natural killer cell-mediated augmentation of complement synthesis. Abstract

Bukh, Jens

Copenhagen University Hospital 11/20/2013 5.40 Journal of virology
Hypervariable region 1 deletion and required adaptive envelope mutations confer decreased dependency on scavenger receptor class B type I and low-density lipoprotein receptor for hepatitis C virus. Abstract

Pietschmann, Thomas

Centre for Experimental and Clinical Infection Research 10/30/2013 5.40 Journal of virology
Apolipoprotein E codetermines tissue tropism of hepatitis C virus and is crucial for viral cell-to-cell transmission by contributing to a postenvelopment step of assembly. Abstract

Pietschmann, Thomas

Centre for Experimental and Clinical Infection Research 10/02/2013 5.40 Journal of virology
Characterization of hepatitis C virus intra- and intergenotypic chimeras reveals a role of the glycoproteins in virus envelopment. Abstract

Bartenschlager, Ralf

Heidelberg University 07/24/2013 5.40 Journal of virology
Morphological and biochemical characterization of the membranous hepatitis C virus replication compartment. Abstract

Baumert, Thomas F

Inserm, U748, Strasbourg 07/17/2013 5.40 Journal of virology
Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes by using monoclonal antibodies. Abstract

Rice, Charles M

The Rockefeller University 05/22/2013 5.40 Journal of virology
Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission. Abstract

Ray, Ranjit

Saint Louis University 05/08/2013 5.40 Journal of virology
Hepatitis C virus infection upregulates CD55 expression on the hepatocyte surface and promotes association with virus particles. Abstract

Ray, Ranjit

Saint Louis University 03/13/2013 5.40 Journal of virology
Hepatitis C virus suppresses C9 complement synthesis and impairs membrane attack complex function. Abstract

Rice, Charles M

The Rockefeller University 02/13/2013 5.40 Journal of virology
Genetic and functional characterization of the N-terminal region of the hepatitis C virus NS2 protein. Abstract

Rehermann, Barbara

National Institutes of Health 02/06/2013 5.40 Journal of virology
The frequency of CD127(+) hepatitis C virus (HCV)-specific T cells but not the expression of exhaustion markers predicts the outcome of acute HCV infection. Abstract

Lemon, Stanley M

The University of North Carolina at Chapel Hill 01/30/2013 5.40 Journal of virology
Contrasting roles of mitogen-activated protein kinases in cellular entry and replication of hepatitis C virus: MKNK1 facilitates cell entry. Abstract

Pietschmann, Thomas

Centre for Experimental and Clinical Infection Research 11/21/2012 5.40 Journal of virology
Subcellular localization and function of an epitope-tagged p7 viroporin in hepatitis C virus-producing cells. Abstract

Bukh, Jens

Copenhagen University Hospital 11/14/2012 5.40 Journal of virology
Characterization of hepatitis C virus recombinants with chimeric E1/E2 envelope proteins and identification of single amino acids in the E2 stem region important for entry. Abstract

Ray, Ranjit

Saint Louis University 10/03/2012 5.40 Journal of virology
Hepatitis C virus induces epithelial-mesenchymal transition in primary human hepatocytes. Abstract

Baumert, Thomas F

Inserm, U748, Strasbourg 08/15/2012 5.40 Journal of virology
Reconstitution of the entire hepatitis C virus life cycle in nonhepatic cells. Abstract

Ray, Ranjit

Saint Louis University 07/03/2012 5.40 Journal of virology
Hepatitis C virus-mediated inhibition of cathepsin S increases invariant-chain expression on hepatocyte surface. Abstract

Lemon, Stanley M

The University of North Carolina at Chapel Hill 04/24/2012 5.40 Journal of virology
Base pairing between hepatitis C virus RNA and microRNA 122 3' of its seed sequence is essential for genome stabilization and production of infectious virus. Abstract

Ray, Ranjit

Saint Louis University 03/28/2012 5.40 Journal of virology
Hepatitis C virus activates the mTOR/S6K1 signaling pathway in inhibiting IRS-1 function for insulin resistance. Abstract

McKeating, Jane A

University of Birmingham 02/08/2012 5.40 Journal of virology
Hepatitis C virus induces CD81 and claudin-1 endocytosis. Abstract

Ray, Ranjit

Saint Louis University 12/14/2011 5.40 Journal of virology
Hepatitis C virus proteins inhibit C3 complement production. Abstract

Bartenschlager, Ralf

Heidelberg University 05/04/2011 5.40 Journal of virology
NS4B self-interaction through conserved C-terminal elements is required for the establishment of functional hepatitis C virus replication complexes. Abstract

Kato, Nobuyuki

Okayama University Graduate School of Medicine 05/04/2011 5.40 Journal of virology
Hepatitis C virus hijacks P-body and stress granule components around lipid droplets. Abstract

Thimme, Robert

University of Freiburg 03/02/2011 5.40 Journal of virology
Immunodominance of HLA-A2-restricted hepatitis C virus-specific CD8+ T cell responses is linked to naive-precursor frequency. Abstract

Ray, Ranjit

Saint Louis University 02/23/2011 5.40 Journal of virology
Transcriptional repression of C4 complement by hepatitis C virus proteins. Abstract

Bukh, Jens

Copenhagen University Hospital 12/22/2010 5.40 Journal of virology
Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations. Abstract

Bukh, Jens

Copenhagen University Hospital 12/01/2010 5.40 Journal of virology
Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. Abstract

McKeating, Jane A

University of Birmingham 10/20/2010 5.40 Journal of virology
Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. Abstract

Lemon, Stanley M

The University of North Carolina at Chapel Hill 04/28/2010 5.40 Journal of virology
Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. Abstract

Lemon, Stanley M

The University of North Carolina at Chapel Hill 04/14/2010 5.40 Journal of virology
DDX6 (Rck/p54) is required for efficient hepatitis C virus replication but not for internal ribosome entry site-directed translation. Abstract

Chung, Raymond T

Harvard Medical School 04/07/2010 5.40 Journal of virology
Suppressor of cytokine signaling 3 suppresses hepatitis C virus replication in an mTOR-dependent manner. Abstract

Ray, Ranjit

Saint Louis University 03/31/2010 5.40 Journal of virology
Hepatitis C virus differentially modulates activation of forkhead transcription factors and insulin-induced metabolic gene expression. Abstract

Bukh, Jens

Copenhagen University Hospital 03/03/2010 5.40 Journal of virology
Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. Abstract

Liang, T Jake

National Institutes of Health 01/20/2010 5.40 Journal of virology
Novel function of CD81 in controlling hepatitis C virus replication. Abstract

Rice, Charles M

The Rockefeller University 12/09/2009 5.40 Journal of virology
Genetic analysis of the carboxy-terminal region of the hepatitis C virus core protein. Abstract

Pietschmann, Thomas

Centre for Experimental and Clinical Infection Research 11/04/2009 5.40 Journal of virology
Mouse-specific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line. Abstract

Rice, Charles M

The Rockefeller University 10/07/2009 5.40 Journal of virology
Determinants of the hepatitis C virus nonstructural protein 2 protease domain required for production of infectious virus. Abstract

McKeating, Jane A

University of Birmingham 09/23/2009 5.40 Journal of virology
Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization. Abstract

Bartenschlager, Ralf

Heidelberg University 09/09/2009 5.40 Journal of virology
Role of RNA structures in genome terminal sequences of the hepatitis C virus for replication and assembly. Abstract

Pietschmann, Thomas

Centre for Experimental and Clinical Infection Research 09/02/2009 5.40 Journal of virology
Characterization of determinants important for hepatitis C virus p7 function in morphogenesis by using trans-complementation. Abstract

Ray, Ranjit

Saint Louis University 07/15/2009 5.40 Journal of virology
Hepatitis C virus core protein and cellular protein HAX-1 promote 5-fluorouracil-mediated hepatocyte growth inhibition. Abstract

Lemon, Stanley M

The University of North Carolina at Chapel Hill 05/20/2009 5.40 Journal of virology
Impaired replication of hepatitis C virus containing mutations in a conserved NS5B retinoblastoma protein-binding motif. Abstract

McKeating, Jane A

University of Birmingham 04/08/2009 5.40 Journal of virology
Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. Abstract

Kato, Nobuyuki

Okayama University Graduate School of Medicine 12/24/2008 5.40 Journal of virology
Arsenic trioxide inhibits hepatitis C virus RNA replication through modulation of the glutathione redox system and oxidative stress. Abstract

Baumert, Thomas F

Inserm, U748, Strasbourg 05/02/2013 5.27 Expert opinion on investigational drugs
Synthetic anti-lipopolysaccharide peptides and hepatitis C virus infection. Abstract

Bartenschlager, Ralf

Heidelberg University 11/21/2013 5.25 Journal of medicinal chemistry
On the history of hepatitis C virus cell culture systems. Abstract

Couch, Fergus J

University of Southern California/Norris Comprehensive Cancer Center 01/07/2012 5.25 Breast cancer research : BCR
No evidence for association of inherited variation in genes involved in mitosis and percent mammographic density. Abstract

Perelson, Alan S

Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545 03/14/2013 5.22 PLoS computational biology
Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model. Abstract

Fan, Jia

Fudan University 03/05/2013 5.11 Journal of proteome research
Quantitative proteomic analysis identified paraoxonase 1 as a novel serum biomarker for microvascular invasion in hepatocellular carcinoma. Abstract

Pineda, Juan A

Hospital Universitario de Valme 12/12/2012 5.07 The Journal of antimicrobial chemotherapy
A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients. Abstract

Resino, Salvador

Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid 01/31/2012 5.07 The Journal of antimicrobial chemotherapy
Plasma IL-6 and IL-9 predict the failure of interferon-α plus ribavirin therapy in HIV/HCV-coinfected patients. Abstract

Resino, Salvador

Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid 01/14/2011 5.07 The Journal of antimicrobial chemotherapy
Sustained virological response to interferon-α plus ribavirin decreases inflammation and endothelial dysfunction markers in HIV/HCV co-infected patients. Abstract

Soriano, Vincent

Hospital Carlos III 12/23/2009 5.07 The Journal of antimicrobial chemotherapy
Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. Abstract

Resino, Salvador

Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid 12/16/2009 5.07 The Journal of antimicrobial chemotherapy
Association between plasma levels of eotaxin (CCL-11) and treatment response to interferon-alpha and ribavirin in HIV/HCV co-infected patients. Abstract

Fan, J

Fudan University 09/03/2013 5.04 British journal of cancer
Prognostic value of peritumoral heat-shock factor-1 in patients receiving resection of hepatocellular carcinoma. Abstract

Cheng, A-L

National Taiwan University Hospital 12/20/2012 5.04 British journal of cancer
Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma. Abstract

Cheng, A-L

National Taiwan University Hospital 10/11/2012 5.04 British journal of cancer
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems. Abstract

Narod, S A

University of Toronto 05/15/2012 5.04 British journal of cancer
Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Abstract

He, X

Shanghai Jiao Tong University School of Medicine 11/23/2010 5.04 British journal of cancer
The role of microRNAs in liver cancer progression. Abstract

Cheng, A-L

National Taiwan University Hospital 02/16/2010 5.04 British journal of cancer
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Abstract

Narod, S A

University of Toronto 04/29/2009 5.04 British journal of cancer
Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband. Abstract

Narod, S A

University of Toronto 12/16/2008 5.04 British journal of cancer
Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation. Abstract

Lemon, Stanley M

The University of North Carolina at Chapel Hill 05/22/2013 4.93 RNA biology
miR-122 and the Hepatitis C RNA genome: more than just stability. Abstract

Bartenschlager, Ralf

Heidelberg University 03/01/2011 4.93 RNA biology
Hepatitis C virus and host cell lipids: an intimate connection. Abstract

Pietschmann, Thomas

Centre for Experimental and Clinical Infection Research 03/06/2013 4.93 Current topics in microbiology and immunology
Cell culture systems for hepatitis C virus. Abstract

Ploss, Alexander

The Rockefeller University 03/06/2013 4.93 Current topics in microbiology and immunology
Animal models for hepatitis C. Abstract

Baumert, Thomas F

Inserm, U748, Strasbourg 03/06/2013 4.93 Current topics in microbiology and immunology
Hepatitis C virus entry. Abstract

Rice, Charles M

The Rockefeller University 03/06/2013 4.93 Current topics in microbiology and immunology
Innate immune responses to hepatitis C virus. Abstract

Thimme, Robert

University of Freiburg 03/06/2013 4.93 Current topics in microbiology and immunology
Adaptive immune responses in hepatitis C virus infection. Abstract

Lemon, Stanley M

The University of North Carolina at Chapel Hill 03/06/2013 4.93 Current topics in microbiology and immunology
Liver injury and disease pathogenesis in chronic hepatitis C. Abstract

Pawlotsky, Jean-Michel

Department of Virology, Hôpital Henri Mondor, Université Paris-Est Créteil 03/06/2013 4.93 Current topics in microbiology and immunology
Treatment of chronic hepatitis C: current and future. Abstract

Cacoub, P

Laboratoire de Biologie et Thérapeutique des Pathologies Immunitaires, Centre National de la Recherche Sientifique, Universite Pierre et Marrie C… 10/27/2010 4.85 Arthritis care & research
Hepatitis C virus-associated polyarteritis nodosa. Abstract

Liang, T Jake

National Institutes of Health 11/25/2013 4.84 Antimicrobial agents and chemotherapy
Novel cell-based hepatitis C virus infection assay for quantitative high-throughput screening of anti-hepatitis C virus compounds. Abstract

Chung, Raymond T

Harvard Medical School 11/22/2010 4.77 The Journal of biological chemistry
HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NFkappaB. Abstract

Bartenschlager, Ralf

Heidelberg University 11/05/2010 4.77 The Journal of biological chemistry
Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. Abstract

McKeating, Jane A

University of Birmingham 04/07/2010 4.77 The Journal of biological chemistry
Claudin association with CD81 defines hepatitis C virus entry. Abstract

Pawlotsky, Jean-Michel

Department of Virology, Hôpital Henri Mondor, Université Paris-Est Créteil 10/06/2009 4.77 The Journal of biological chemistry
Hepatitis C virus proteins induce lipogenesis and defective triglyceride secretion in transgenic mice. Abstract

Cristofanilli, Massimo

The University of Texas M. D. Anderson Cancer Center 11/29/2010 4.77 Cancer
Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Abstract

Cheng, Ann-Lii

National Taiwan University Hospital 09/27/2010 4.77 Cancer
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Abstract

Kumada, Hiromitsu

Toranomon Hospital 01/26/2009 4.77 Cancer
High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Abstract

Soriano, Vicente

Hospital Universitario de Valme 10/14/2011 4.75 Current opinion in HIV and AIDS
Host genetics. Abstract

02/23/2011 4.73 Obstetrics and gynecology
Committee Opinion No. 482: Colonoscopy and colorectal cancer screening strategies. Abstract

07/28/2010 4.73 Obstetrics and gynecology
ACOG Committee Opinion No. 463: Cervical cancer in adolescents: screening, evaluation, and management. Abstract

03/23/2009 4.73 Obstetrics and gynecology
ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Abstract

Maehara, Y

Kyushu University 12/24/2010 4.61 The British journal of surgery
Prognostic importance of the gross classification of hepatocellular carcinoma in living donor-related liver transplantation. Abstract

Buchholz, Thomas A

the University of Texas MD Anderson Cancer Center 08/20/2009 4.55 Journal of the American College of Surgeons
Breast-conserving surgery in older patients with invasive breast cancer: current patterns of treatment across the United States. Abstract

Tamimi, Rulla M

Washington University in St Louis School of Medicine 10/18/2013 4.43 Breast cancer research and treatment
Reproductive factors and risk of premenopausal breast cancer by age at diagnosis: are there differences before and after age 40? Abstract

Tamimi, Rulla M

Harvard School of Public Health 04/23/2013 4.43 Breast cancer research and treatment
Radial scars and subsequent breast cancer risk: results from the Nurses' Health Studies. Abstract

Tamimi, Rulla M

Harvard School of Public Health 10/21/2012 4.43 Breast cancer research and treatment
Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, growth hormone, and mammographic density in the Nurses' Health Studies. Abstract

Tamimi, Rulla M

Harvard School of Public Health 05/24/2012 4.43 Breast cancer research and treatment
Adolescent intakes of vitamin D and calcium and incidence of proliferative benign breast disease. Abstract

Tamimi, Rulla M

Harvard School of Public Health 07/05/2011 4.43 Breast cancer research and treatment
COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. Abstract

Narod, Steven A

University of Toronto 04/01/2011 4.43 Breast cancer research and treatment
The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer. Abstract

Narod, Steven A

University of Toronto 01/09/2011 4.43 Breast cancer research and treatment
Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Abstract

Narod, Steven A

Womens College Research Institute 01/04/2011 4.43 Breast cancer research and treatment
Age of diagnosis, tumor size, and survival after breast cancer: implications for mammographic screening. Abstract

Sichuan University 08/12/2009 4.43 Breast cancer research and treatment
Postmenopausal estrogen monotherapy-associated breast cancer risk is modified by CYP17A1_-34_T>C polymorphism. Abstract

Couch, Fergus J

Mayo Clinic College of Medicine 12/11/2008 4.43 Breast cancer research and treatment
No evidence that GATA3 rs570613 SNP modifies breast cancer risk. Abstract

Resino, Salvador

Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid 11/15/2013 4.43 Journal of acquired immune deficiency syndromes (1999)
Prediction of hepatic fibrosis in patients coinfected with HIV and hepatitis C virus based on genetic markers. Abstract

Soriano, Vincent

Hospital Carlos III 03/15/2010 4.43 Journal of acquired immune deficiency syndromes (1999)
Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapse. Abstract

Prins, Maria

University of California 02/08/2012 4.31 Addiction (Abingdon, England)
The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam. Abstract

Cacoub, Patrice

Groupe Hospitalier Pitié-Salpétrière 11/30/2012 4.31 Current opinion in rheumatology
Cryoglobulinemia vasculitis: an update. Abstract

McKeating, J A

University of Birmingham 10/21/2013 4.30 Antiviral research
Differential effect of p7 inhibitors on hepatitis C virus cell-to-cell transmission. Abstract

Wei, Lai

Peking University Hepatology Institute 02/16/2013 4.30 Antiviral research
BST2/Tetherin inhibits hepatitis C virus production in human hepatoma cells. Abstract

Chung, Raymond T

Harvard Medical School 12/10/2012 4.30 Antiviral research
SOCS1 abrogates IFN's antiviral effect on hepatitis C virus replication. Abstract

Pineda, Juan A

Hospital Universitario de Valme 06/29/2012 4.30 Antiviral research
HIV-coinfection leads to a modest increase in plasma HCV-RNA load in patients with chronic HCV infection. Abstract

Pineda, Juan Antonio

Hospital Universitario de Valme 06/07/2012 4.30 Antiviral research
No influence of antiretroviral therapy on the mutation rate of the HCV NS5B polymerase in HIV/HCV-coinfected patients. Abstract

Pietschmann, Thomas

Centre for Experimental and Clinical Infection Research 12/15/2010 4.30 Antiviral research
Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity. Abstract

Lemon, Stanley M

The University of North Carolina at Chapel Hill 07/14/2010 4.30 Antiviral research
miR-122 does not modulate the elongation phase of hepatitis C virus RNA synthesis in isolated replicase complexes. Abstract

Rice, Charles M

The Rockefeller University 02/25/2010 4.30 Antiviral research
Creation and characterization of a cell-death reporter cell line for hepatitis C virus infection. Abstract

Wei, Lin

Hebei Medical University 07/29/2009 4.30 Antiviral research
A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice. Abstract

Kato, Nobuyuki

Okayama University Graduate School of Medicine 02/06/2009 4.30 Antiviral research
Replicons from genotype 1b HCV-positive sera exhibit diverse sensitivities to anti-HCV reagents. Abstract

Lemon, Stanley M

The University of North Carolina at Chapel Hill 07/18/2013 4.24 Cancer letters
Mechanisms of HCV-induced liver cancer: what did we learn from in vitro and animal studies? Abstract

He, Xianghuo

Fudan University 08/22/2011 4.24 Cancer letters
Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma. Abstract

Baumert, Thomas F

Inserm, U748, Strasbourg 06/23/2009 4.21 Journal of innate immunity
Toll-like receptor 2 senses hepatitis C virus core protein but not infectious viral particles. Abstract

Llovet, Josep M

Mount Sinai School of Medicine 04/23/2009 4.19 Current opinion in gastroenterology
Pathogenesis of hepatocellular carcinoma and molecular therapies. Abstract

Maehara, Yoshihiko

Kyushu University 12/28/2011 4.17 Annals of surgical oncology
Predictors for microinvasion of small hepatocellular carcinoma ≤ 2 cm. Abstract

Fan, Jia

Fudan University 07/27/2011 4.17 Annals of surgical oncology
Infiltrating memory/senescent T cell ratio predicts extrahepatic metastasis of hepatocellular carcinoma. Abstract

Maehara, Yoshihiko

Kyushu University 11/13/2010 4.17 Annals of surgical oncology
Evaluation of ERCC1 expression for cisplatin sensitivity in human hepatocellular carcinoma. Abstract

Maehara, Yoshihiko

Kyushu University 04/22/2010 4.17 Annals of surgical oncology
Predictors of extrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma. Abstract

Maehara, Yoshihko

Kyushu University 03/05/2010 4.17 Annals of surgical oncology
Improved results of a surgical resection for the recurrence of hepatocellular carcinoma after living donor liver transplantation. Abstract

Maehara, Yoshihiko

Kyushu University 10/14/2009 4.17 Annals of surgical oncology
Long-term results of hepatic resection combined with intraoperative local ablation therapy for patients with multinodular hepatocellular carcinomas. Abstract

Chayama, Kazuaki

Hiroshima University 10/05/2012 4.16 Journal of gastroenterology
Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis. Abstract

Kumada, Hiromitsu

Toranomon Hospital 08/09/2012 4.16 Journal of gastroenterology
Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study. Abstract

Kumada, Hiromitsu

Toranomon Hospital 03/23/2012 4.16 Journal of gastroenterology
Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. Abstract

Chayama, Kazuaki

Hiroshima University 02/18/2012 4.16 Journal of gastroenterology
IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients. Abstract

Chayama, Kazuaki

Hiroshima University 03/04/2011 4.16 Journal of gastroenterology
Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy. Abstract

Kumada, Hiromitsu

Toranomon Hospital 01/19/2011 4.16 Journal of gastroenterology
Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C. Abstract

Cheng, Ann-Lii

National Taiwan University Hospital 06/22/2010 4.16 Journal of gastroenterology
Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. Abstract

Pawlotsky, Jean-Michel

Department of Virology, Hôpital Henri Mondor, Université Paris-Est Créteil 02/20/2013 4.15 Journal of clinical microbiology
Multicenter quality control of hepatitis C virus protease inhibitor resistance genotyping. Abstract

Wedemeyer, Heiner

Hannover Medical School 03/29/2010 4.15 Journal of clinical microbiology
Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics. Abstract

Pawlotsky, Jean-Michel

Department of Virology, Hôpital Henri Mondor, Université Paris-Est Créteil 04/15/2009 4.15 Journal of clinical microbiology
Performance of the Abbott real-time PCR assay using m2000sp and m2000rt for hepatitis C virus RNA quantification. Abstract

Resino, Salvador

Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid 12/21/2013 4.13 The Journal of infection
Incidence and mortality of tuberculosis disease in Spain between 1997 and 2010: impact of human immunodeficiency virus (HIV) status. Abstract

Resino, Salvador

Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid 11/01/2013 4.13 The Journal of infection
Vitamin D deficiency is associated with severity of liver disease in HIV/HCV coinfected patients. Abstract

Pineda, Juan A

Hospital Universitario de Valme 03/28/2013 4.13 The Journal of infection
Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response. Abstract

Resino, Salvador

Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid 10/26/2012 4.13 The Journal of infection
IL28B polymorphisms are associated with severity of liver disease in human immunodeficiency virus (HIV) patients coinfected with hepatitis C virus. Abstract

Jemal, Ahmedin

Surveillance Research, American Cancer Society, Atlanta, GA 02/28/2011 4.12 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Breast cancer incidence rates in U.S. women are no longer declining. Abstract

Couch, Fergus J

Mayo Clinic College of Medicine 05/19/2009 4.12 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Genetic variation in the chromosome 17q23 amplicon and breast cancer risk. Abstract

Sichuan University 03/31/2009 4.12 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Cervical carcinoma and sexual behavior: collaborative reanalysis of individual data on 15,461 women with cervical carcinoma and 29,164 women without cervical carcinoma from 21 epidemiological studies. Abstract

Buchholz, Thomas A

the University of Texas MD Anderson Cancer Center 08/15/2008 4.11 International journal of radiation oncology, biology, physics
Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach. Abstract

Chayama, Kazuaki

Hiroshima University 12/20/2013 4.09 PloS one
HLA-DQB1*03 confers susceptibility to chronic hepatitis C in Japanese: a genome-wide association study. Abstract

Dore, Gregory J

The University of New South Wales 11/20/2013 4.09 PloS one
Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection. Abstract

Lemon, Stanley M

The University of North Carolina at Chapel Hill 10/09/2013 4.09 PloS one
microRNA-122 abundance in hepatocellular carcinoma and non-tumor liver tissue from Japanese patients with persistent HCV versus HBV infection. Abstract

Fan, Jia

Fudan University 09/13/2013 4.09 PloS one
Promoting colonization in metastatic HCC cells by modulation of autophagy. Abstract

Kato, Nobuyuki

Okayama University Graduate School of Medicine 08/30/2013 4.09 PloS one
New preclinical antimalarial drugs potently inhibit hepatitis C virus genotype 1b RNA replication. Abstract

Wei, Lai

Peking University Hepatology Institute 06/24/2013 4.09 PloS one
Determination of the human antibody response to the neutralization epitopes encompassing amino acids 313-327 and 432-443 of hepatitis C virus E1E2 glycoproteins. Abstract

Baumert, Thomas F

Inserm, U748, Strasbourg 05/21/2013 4.09 PloS one
A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission. Abstract

Fan, Jia

Fudan University 04/25/2013 4.09 PloS one
Genetic polymorphism of the kinesin-like protein KIF1B gene and the risk of hepatocellular carcinoma. Abstract

Fan, Jia

Fudan University 02/28/2013 4.09 PloS one
α-Fetoprotein promoter-driven Cre/LoxP-switched RNA interference for hepatocellular carcinoma tissue-specific target therapy. Abstract

He, Xiaoshun

Sun Yat-sen University 12/20/2012 4.09 PloS one
Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis. Abstract

He, Xianghuo

Fudan University 11/07/2012 4.09 PloS one
MicroRNA-550a acts as a pro-metastatic gene and directly targets cytoplasmic polyadenylation element-binding protein 4 in hepatocellular carcinoma. Abstract

Wei, Lixin

Second Military Medical University 08/28/2012 4.09 PloS one
Mesenchymal stem cells in inflammation microenvironment accelerates hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition. Abstract

He, XiaoShun

Sun Yat-sen University 07/26/2012 4.09 PloS one
Salvage liver transplantation for patients with recurrent hepatocellular carcinoma after curative resection. Abstract

Wei, Lai

Peking University Hepatology Institute 06/29/2012 4.09 PloS one
Effects of interferon-alpha treatment on the incidence of hyperglycemia in chronic hepatitis C patients: a systematic review and meta-analysis. Abstract

Pietschmann, Thomas

Centre for Experimental and Clinical Infection Research 04/25/2012 4.09 PloS one
Bile acids specifically increase hepatitis C virus RNA-replication. Abstract

Chung, Raymond T

Harvard Medical School 02/16/2012 4.09 PloS one
ARF1 and GBF1 generate a PI4P-enriched environment supportive of hepatitis C virus replication. Abstract

Kato, Naoya

Shandong University 01/03/2012 4.09 PloS one
ABO blood group and the risk of hepatocellular carcinoma: a case-control study in patients with chronic hepatitis B. Abstract

Prins, Maria

University of California 11/15/2011 4.09 PloS one
Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. Abstract

McKeating, Jane A

University of Birmingham 09/30/2011 4.09 PloS one
Rituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion on virus infectivity. Abstract

Prins, Maria

University of California 09/14/2011 4.09 PloS one
People with multiple tattoos and/or piercings are not at increased risk for HBV or HCV in The Netherlands. Abstract

Chayama, Kazuaki

Hiroshima University 08/23/2011 4.09 PloS one
Hepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouse. Abstract

Ray, Ranjit

Saint Louis University 08/22/2011 4.09 PloS one
A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection. Abstract

Kato, Nobuyuki

Okayama University Graduate School of Medicine 01/11/2011 4.09 PloS one
The ESCRT system is required for hepatitis C virus production. Abstract

Pawlotsky, Jean-Michel

Department of Virology, Hôpital Henri Mondor, Université Paris-Est Créteil 12/08/2009 4.09 PloS one
Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. Abstract

Wedemeyer, H

Hannover Medical School 11/19/2013 4.09 Journal of viral hepatitis
Hepatitis C virus core antigen testing in liver and kidney transplant recipients. Abstract

Zeuzem, S

Monash Medical Centre and Monash University 10/30/2013 4.09 Journal of viral hepatitis
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. Abstract

Zeuzem, S

Monash Medical Centre and Monash University 06/21/2013 4.09 Journal of viral hepatitis
Impact of ribavirin priming on viral kinetics and treatment response in chronic hepatitis C genotype 1 infection. Abstract

Resino, S

Laboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid 12/20/2012 4.09 Journal of viral hepatitis
IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients. Abstract

Wei, L

Peking University Hepatology Institute 07/30/2012 4.09 Journal of viral hepatitis
Association of suppressor of cytokine signalling 3 polymorphisms with insulin resistance in patients with chronic hepatitis C. Abstract

Kumada, H

Toranomon Hospital 07/13/2012 4.09 Journal of viral hepatitis
Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b. Abstract

McKeating, J A

University of Birmingham 04/13/2012 4.09 Journal of viral hepatitis
Hepatitis C virus and the brain. Abstract

Zeuzem, S

Monash Medical Centre and Monash University 03/21/2012 4.09 Journal of viral hepatitis
Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3. Abstract

Cacoub, P

Laboratoire de Biologie et Thérapeutique des Pathologies Immunitaires, Centre National de la Recherche Sientifique, Universite Pierre et Marrie C… 01/03/2012 4.09 Journal of viral hepatitis
Evolution of biomarkers of liver fibrosis and liver insufficiency in hepatitis C virus-infected patients treated with pegylated interferon plus ribavirin and rituximab. Abstract

Wedemeyer, H

Hannover Medical School 11/07/2011 4.09 Journal of viral hepatitis
Immunosuppression, liver injury and post-transplant HCV recurrence. Abstract

Nguyen, M H

Stanford University Medical Center 10/07/2011 4.09 Journal of viral hepatitis
Prospective study of risk factors for hepatitis C virus acquisition by Caucasian, Hispanic, and Asian American patients. Abstract

Chayama, K

Laboratory for Digestive Diseases, Center for Genomic Medicine, RIKEN, Hiroshima 09/14/2011 4.09 Journal of viral hepatitis
Serum PAI-1 is a novel predictor for response to pegylated interferon-α-2b plus ribavirin therapy in chronic hepatitis C virus infection. Abstract

Wei, L

Peking University Hepatology Institute 08/04/2011 4.09 Journal of viral hepatitis
IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. Abstract

Chayama, K

Laboratory for Digestive Diseases, Center for Genomic Medicine, RIKEN, Hiroshima 05/23/2011 4.09 Journal of viral hepatitis
IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma. Abstract

Dore, G J

The University of New South Wales 02/17/2011 4.09 Journal of viral hepatitis
Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: a population-based cohort study, 1992-2007. Abstract

Royal Derby Hospital 12/07/2010 4.09 Journal of viral hepatitis
A comparison of the natural history and outcome of treatment for Asian and non-Asian hepatitis C-infected patients.